Pharmaceutical, life science, and biotech incubators and accelerators are designed to assist with the growth and success of companies by providing various types of business support and resources. Specifically, incubators are companies formed in the "idea" stage and need assistance from the ground-up. Accelerators, on the other hand, need assistance in progressing their business. Both incubators and accelerators often require support from established companies such as a physical place to work, shared laboratory spaces, capital, and networking connections.
There will always be challenges for the pharmaceutical industry where sustainability is concerned, but it needn’t be a bitter pill to swallow.
From complex medication requiring specific packaging to tight production schedules, the industry faces stubborn obstacles in ensuring that it improves the wellbeing and health of humans while not harming the planet.
The EPA proposes to issue a final rule for hazardous waste pharmaceuticals in July 2018. This rule will impact almost every level of pharmaceutical sales and marketing such as pharmacies, doctor offices, clinics, veterinary clinics, and retail operations.
Company ranks in top 10% of Pharmaceutical and Biotech Sector on the issues Americans care about most.
Press Release
NEW YORK, December 14, 2017 /3BL Media/ -- Bristol-Myers Squibb Company (NYSE: BMY) was named one of America’s Most JUST Companies, according to Forbes and JUST Capital, a nonprofit that ranks the largest publicly traded corporations in the United States on the issues Americans care about most. The company ranked third in the Pharmaceutical & Biotech sector and 32nd overall out of 1,000 of the largest publicly-traded companies in the United States.
Every day, many patients across the U.S. face access challenges to medications or treatments they have been prescribed because they do not have insurance, their insurance does not cover the prescribed product or treatment, or they struggle to navigate the complex insurance process. To address these and other obstacles, Sanofi supports many of these patients with their specific challenges.
Innovations in medicine and medical technology are designed to serve the 600 million people living in the most developed countries, and that’s who they typically benefit. But what about the other 6 billion?
Multimedia with summary
On Wednesday, November 2nd, Andrew Witty, GSK CEO, will join Seth Berkley, GAVI Alliance CEO, at Fortune Brainstorm Health for a discussion on “The Other Six Billion” referring to the areas of the world that are traditionally not served by innovations in medicine and medical technology. Outside of the most developed countries infectious diseases—including malaria, tuberculosis and HIV—still kill an astounding 15 million people a year.
NEW YORK, September 13, 2016 /3BL Media/ Bristol-Myers Squibb Company (NYSE:BMY) has earned a place on the prestigious Dow Jones Sustainability Index (DJSI) North America for the second consecutive year. The index recognizes public companies for outstanding performance across economic, environmental and social factors, and serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
Bristol-Myers Squibb is one of eight pharmaceutical, biotechnology and life sciences companies included on the 2016 North America Index.
The UPL seeks to improve how complex topics are communicated to patients; Company launches UPL.org to make principles and tools widely available to others
Press Release
PRINCETON, N.J., June 16, 2016 /3BL Media/ Bristol-Myers Squibb (NYSE:BMY) today announced its commitment to moving toward a new way of communicating with patients and caregivers: the Universal Patient Language (UPL). The UPL addresses widely voiced concerns among consumers and health care advocates that communications about medicines are not designed for an optimal patient experience.
